Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 17/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.53 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898644 | 0.94 | GCK (0.54) | GCKKCNH2KCNMA1NPC1RAB9A | |
| SCHEMBL2726680 | 0.94 | GCK (0.54) | GCKKCNH2KCNMA1NPC1RAB9A | |
| SCHEMBL9898775 | 0.87 | GCK (0.70) | GCKKCNH2 | |
| SCHEMBL2724721 | 0.87 | GCK (0.70) | GCKKCNH2 | |
| SCHEMBL9897930 | 0.87 | GCK (0.70) | GCKKCNH2 | |
| SCHEMBL9898171 | 0.86 | GCK (0.53) | GCKKCNH2KCNMA1NPC1RAB9A | |
| SCHEMBL2708202 | 0.85 | GCK (0.53) | GCKKCNH2KCNMA1NPC1RAB9A | |
| SCHEMBL9900415 | 0.85 | GCK (0.53) | GCKKCNH2KCNMA1NPC1RAB9A | |
| SCHEMBL9898608 | 0.83 | GCK (0.51) | GCKKCNH2KCNMA1NPC1RAB9A | |
| SCHEMBL1271326 | 0.83 | NR1H4 (0.43) | GCKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8450494-B2 | Disubstituted benzamide derivatives as glucokinase (GK) activators | CADILA HEALTHCARE LIMITED (IN) | 2013-05-28 | — | — | US | disclosed |
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | CADILA HEALTHCARE LIMITED (IN) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149704-A1 | DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS | GCKR, GCK, GK | GCK 2/4885KCNH2 256/4885KCNMA1 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.